FI3206692T3 - Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja - Google Patents
Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja Download PDFInfo
- Publication number
- FI3206692T3 FI3206692T3 FIEP15851238.4T FI15851238T FI3206692T3 FI 3206692 T3 FI3206692 T3 FI 3206692T3 FI 15851238 T FI15851238 T FI 15851238T FI 3206692 T3 FI3206692 T3 FI 3206692T3
- Authority
- FI
- Finland
- Prior art keywords
- compound
- use according
- liver disease
- fatty liver
- alcohol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064358P | 2014-10-15 | 2014-10-15 | |
| US201462092041P | 2014-12-15 | 2014-12-15 | |
| PCT/US2015/055487 WO2016061195A1 (en) | 2014-10-15 | 2015-10-14 | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3206692T3 true FI3206692T3 (fi) | 2024-05-06 |
Family
ID=55747256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15851238.4T FI3206692T3 (fi) | 2014-10-15 | 2015-10-14 | Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10238659B2 (enExample) |
| EP (2) | EP4353310A3 (enExample) |
| JP (1) | JP6761410B2 (enExample) |
| KR (1) | KR102435956B1 (enExample) |
| CN (2) | CN111557942B (enExample) |
| AU (1) | AU2015333645B2 (enExample) |
| BR (1) | BR112017007860B1 (enExample) |
| CA (1) | CA2964625C (enExample) |
| DK (1) | DK3206692T3 (enExample) |
| ES (1) | ES2978871T3 (enExample) |
| FI (1) | FI3206692T3 (enExample) |
| IL (1) | IL251729B (enExample) |
| MX (1) | MX2017004943A (enExample) |
| NZ (1) | NZ731060A (enExample) |
| PH (1) | PH12017500710B1 (enExample) |
| PL (1) | PL3206692T3 (enExample) |
| PT (1) | PT3206692T (enExample) |
| RU (1) | RU2718921C2 (enExample) |
| SG (1) | SG11201703024VA (enExample) |
| UA (1) | UA123537C2 (enExample) |
| WO (1) | WO2016061195A1 (enExample) |
| ZA (1) | ZA201702813B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12017500710B1 (en) | 2014-10-15 | 2024-01-17 | Corcept Therapeutics Inc | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
| KR102589213B1 (ko) * | 2018-06-04 | 2023-10-12 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 피리미딘 사이클로헥세닐 글루코코르티코이드 수용체 조절제 |
| US20220288091A1 (en) | 2019-03-18 | 2022-09-15 | Lynnette K. NIEMAN | Method for Improving Insulin Sensitivity |
| BR112022022473A2 (pt) * | 2020-05-06 | 2022-12-13 | Corcept Therapeutics Inc | Formulações de moduladores de receptor de glucocorticoide ciclo-hexil pirimidina |
| US11548856B2 (en) | 2020-05-06 | 2023-01-10 | Corcept Therapeutics Incorporated | Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators |
| KR102481705B1 (ko) * | 2020-08-04 | 2022-12-27 | 연세대학교 산학협력단 | 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물 |
| IL303881A (en) * | 2020-12-21 | 2023-08-01 | Corcept Therapeutics Inc | Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators |
| EP4333848A4 (en) * | 2021-05-05 | 2025-03-19 | Corcept Therapeutics Incorporated | Methods for reducing liver fat and treating fatty liver disease |
| WO2025174745A1 (en) * | 2024-02-12 | 2025-08-21 | Corcept Therapeutics Incorporated | MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2153546A (en) | 1936-07-29 | 1939-04-11 | Universal Draft Gear Attachmen | Hand brake actuating mechanism |
| US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
| GB0213745D0 (en) * | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
| EP1534273A4 (en) | 2002-07-18 | 2007-08-22 | Bristol Myers Squibb Co | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD |
| AU2006247537B2 (en) | 2005-05-18 | 2011-01-06 | Merck Sharp & Dohme Corp. | D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands |
| US8389472B2 (en) * | 2005-08-19 | 2013-03-05 | Amylin Pharmaceuticals, Llc | Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease |
| KR20080065617A (ko) * | 2005-09-19 | 2008-07-14 | 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 | 글루코코티코이드 수용체 발현의 조절 |
| GB0601092D0 (en) * | 2006-01-19 | 2006-03-01 | Daniolabs Ltd | The Prevention Of Systemic Side-Effects Of Glucocorticoids |
| EP2032134B1 (en) | 2006-05-09 | 2015-06-24 | Genzyme Corporation | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| WO2008127591A2 (en) * | 2007-04-13 | 2008-10-23 | Schering Corporation | Pyrimidinedione derivatives and use thereof |
| US8003689B2 (en) | 2008-06-20 | 2011-08-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| JP5511942B2 (ja) | 2009-04-03 | 2014-06-04 | エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト | 組成物及びその使用 |
| EP2685827B1 (en) | 2011-03-18 | 2016-02-03 | Corcept Therapeutics, Inc. | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
| PH12017500710B1 (en) | 2014-10-15 | 2024-01-17 | Corcept Therapeutics Inc | Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists |
-
2015
- 2015-10-14 PH PH1/2017/500710A patent/PH12017500710B1/en unknown
- 2015-10-14 PL PL15851238.4T patent/PL3206692T3/pl unknown
- 2015-10-14 PT PT158512384T patent/PT3206692T/pt unknown
- 2015-10-14 NZ NZ731060A patent/NZ731060A/en unknown
- 2015-10-14 FI FIEP15851238.4T patent/FI3206692T3/fi active
- 2015-10-14 EP EP24157529.9A patent/EP4353310A3/en active Pending
- 2015-10-14 UA UAA201704069A patent/UA123537C2/uk unknown
- 2015-10-14 WO PCT/US2015/055487 patent/WO2016061195A1/en not_active Ceased
- 2015-10-14 MX MX2017004943A patent/MX2017004943A/es active IP Right Grant
- 2015-10-14 US US14/883,369 patent/US10238659B2/en active Active
- 2015-10-14 DK DK15851238.4T patent/DK3206692T3/da active
- 2015-10-14 CA CA2964625A patent/CA2964625C/en active Active
- 2015-10-14 EP EP15851238.4A patent/EP3206692B1/en active Active
- 2015-10-14 KR KR1020177012950A patent/KR102435956B1/ko active Active
- 2015-10-14 ES ES15851238T patent/ES2978871T3/es active Active
- 2015-10-14 AU AU2015333645A patent/AU2015333645B2/en active Active
- 2015-10-14 BR BR112017007860-0A patent/BR112017007860B1/pt active IP Right Grant
- 2015-10-14 SG SG11201703024VA patent/SG11201703024VA/en unknown
- 2015-10-14 RU RU2017114596A patent/RU2718921C2/ru active
- 2015-10-14 JP JP2017520388A patent/JP6761410B2/ja active Active
- 2015-10-14 CN CN202010597452.8A patent/CN111557942B/zh active Active
- 2015-10-14 CN CN201580068262.4A patent/CN107106562B/zh active Active
-
2017
- 2017-04-13 IL IL251729A patent/IL251729B/en active IP Right Grant
- 2017-04-21 ZA ZA2017/02813A patent/ZA201702813B/en unknown
-
2019
- 2019-01-24 US US16/256,295 patent/US10881660B2/en active Active
-
2020
- 2020-12-03 US US17/111,288 patent/US11590135B2/en active Active
-
2023
- 2023-01-26 US US18/101,986 patent/US12226417B2/en active Active
-
2025
- 2025-01-09 US US19/014,779 patent/US20250221995A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3206692T3 (fi) | Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja | |
| PH12016502168A1 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| ME02382B (me) | 2-(2,4,5-supstituisani-anilino) piramidisnki derivati kao egfr modulatori korisni za tretman raka | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| CL2015000578A1 (es) | Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer. | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| MX2016000307A (es) | Farmaco para el tratamiento de la esteatosis hepatica no alcoholica. | |
| EP2696679A4 (en) | 2'-CYAN SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES | |
| FR2997845B1 (fr) | Procede de lissage des cheveux a partir d'une composition contenant de l'acide glyoxylique et/ou un de ses derives | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| PH12015501836A1 (en) | 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors | |
| MX380619B (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| PH12016500885A1 (en) | Novel heterocyclic compounds | |
| EA201300436A1 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| AR067328A1 (es) | Formas amorfas estabilizadas de mesilato de imatinib | |
| FR2977486B1 (fr) | Compositions cosmetiques sous la forme d'emulsions eau-dans-huile comprenant un derive d'acide jasmonique | |
| EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 | |
| FR3022462B1 (fr) | Composition orale d'anticorps anti-tnfalpha | |
| BR122019016794B8 (pt) | derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso no tratamento de uma condição inflamatória e/ou autoimune | |
| BR112015029504A2 (pt) | inibidores quinase | |
| BR112015013414A2 (pt) | derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| EA201390488A1 (ru) | Новые агонисты gpr 119 | |
| BR112014016450A2 (pt) | composto antagonista de leucotrieno b4 | |
| MY166057A (en) | Carbocyclic nucleosides and their pharmaceutical use and compositions | |
| AR112040A1 (es) | Sal de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2-metoxifenil}amino)-1-metil-4,5-dihidro-1h-pirazolo[4,3-h]quinazolina-3-carboxamida, su preparación, y las formulaciones que la contienen |